TRAW Share Price Performance
US$1.24
-10.16 (-89.12%)
84.5% undervalued intrinsic discount
US$8.00
Fair Value
Price US$1.24
AnalystConsensusTarget US$8.00
Fair ValueUS$8.00
Share Pricen/a
Traws Pharma, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
TRAW Community Narratives
AN
Fair Value US$8 84.5% undervalued intrinsic discount
COVID Antivirals And Pandemic Preparedness Will Drive Compelling Long Term Opportunity
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
COVID Antivirals And Pandemic Preparedness Will Drive Compelling Long Term Opportunity
Catalysts About Traws Pharma Traws Pharma is a clinical stage biopharmaceutical company developing oral antivirals for COVID 19 and pandemic influenza, alongside partnering opportunities in oncology. What are the underlying business or industry changes driving this perspective?Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$8
84.5% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
158.8% p.a.
Profit Margin
0.21%
Future PE
9.3x
Price in 2028
US$0.05
Trending Discussion
Recently Updated Narratives
AN
COVID Antivirals And Pandemic Preparedness Will Drive Compelling Long Term Opportunity
Fair Value: US$8 84.5% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Traws Pharma, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.15
- 100.00%
- -321.71%
- 0%
About TRAW
- Founded
- 1998
- Employees
- 7
- CEO
- WebsiteView website
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
